Stryker (SYK) Stock Could Be Below Fair Value With Earnings Near Fair Value
Stryker stock has given investors a 28.3% total return over the past five years, yet its current share price around US$319 sits at a point where the Discounted Cash Flow (DCF) estimate suggests room for upside, while the broader checks paint a more cautious picture.
- A 28.3% return over five years indicates that Stryker has rewarded patient shareholders without delivering an outsized run that would obviously stretch valuation.
- The launch of the Mako RPS handheld robotic system can support growth expectations for Stryker’s orthopedics franchise. However, concerns about hospital capital spending and competitive pressure on pricing may weigh on how much investors are willing to pay for that growth.
- The company screens as undervalued on some metrics but not others, with a mixed valuation score of 3 out of 6 checks that neither clearly flags a bargain nor a clear overvaluation.
The issue now is whether the 20.4% discount implied by the DCF intrinsic value can be trusted more than the more neutral signal from the wider valuation checks when deciding how to think about Stryker’s current price.
Find out why Stryker's -17.0% return over the last year is lagging behind its peers.
Is Stryker a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model values Stryker by projecting future cash that can be returned to shareholders and discounting it back to today. For Stryker, the latest twelve month free cash flow sits at about US$4.6b, and the model applies a growing cash flow profile rather than assuming a decline or a sharp rebound from losses.
On these assumptions, the DCF points to an estimated intrinsic value of about $402 per share, compared with the current share price around $319, implying roughly a 20.4% discount. The recent 5.49% share price drop on worries about hospital spending and competition helps explain why the market price sits below what this cash flow view suggests.
On balance, the Discounted Cash Flow model indicates Stryker stock currently looks undervalued relative to its projected cash generation.
Our Discounted Cash Flow (DCF) analysis suggests Stryker is undervalued by 20.4%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.
Is Stryker Fairly Priced on Earnings?
The P/E ratio is a useful way to think about what you are paying today for each dollar of Stryker’s earnings. On this metric, Stryker trades at about 36.7x earnings, compared with an industry average of roughly 27.5x and a peer average near 28.0x. As a result, the stock sits at a visible premium to the broader medical equipment group.
Taking account of Stryker’s size, margins and risk profile, the tailored fair P/E from this model is 34.7x, only slightly below the current multiple. That gap suggests the stock is not glaringly cheap, but the valuation is also not stretched to an extreme on earnings alone, particularly when set against other large medical equipment companies.
Overall, Stryker appears roughly fairly valued on its P/E multiple, with the current price sitting close to what this earnings-based framework would suggest.
See what the numbers say about this price — find out in our valuation breakdown.
The Stryker Narrative: What Would Justify Today's Price?
Simply Wall St Narratives step in here to spell out what would need to happen to Stryker’s growth, margins and earnings for the stock to be worth materially more or less than today’s price, and they sit on the company’s Community page. Rather than focusing on a single multiple or model output, each one lays out the assumptions behind its view of fair value so you can compare those expectations with Stryker’s actual results over time.
Want to add your own number driven take on Stryker, including a view on whether the new Mako RPS handheld robotic system really earns its place in the story, and see how it stacks up as fresh results and news roll through?
Share a narrative on Stryker to put your assumptions on the record and compare them with how the stock, and the company, actually perform over time.
Do you think there's more to the story for Stryker? Head over to our Community to see what others are saying!
The Bottom Line
For Stryker, the Discounted Cash Flow (DCF) estimate points to meaningful upside from the current share price, while the earnings multiple says the stock is priced about right against large peers. That split reflects a cash flow view that is more generous than what sentiment and comparable valuations currently support. With the broader valuation checks in mixed territory, the key question is whether Stryker’s cash generation and pricing power, including around products like Mako RPS, hold up well enough to close that gap or whether the market ultimately proves that the current discount is justified.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com